Morgan Stanley analyst Matthew Harrison provides commentary on Celgene Corporation (NASDAQ:CELG) ahead of topline data due for its pipeline oral Crohn’s drug GED-0301 …
Celegene raised prices for pipeline drugs Revlimid and Pomalyst by 3%
BMO believes Mongersen has the potential to achieve $4 billion in revenue
J.P.
Celgene Corporation (NASDAQ:CELG) has impending pipeline data on its way in 2H16, with the next few years anticipated to overflow with readouts of Phase …
At a recent dinner with brokerage firm Cowen, CFO Peter Kellogg and Inflammation & Immunology (I&I) President Scott Smith of Celgene Corporation (NASDAQ:CELG) …
Overhang and political rhetoric have paved a tough road for biotech stocks in the past year. Investor concern has been rampant, but the …
Drug giant Celgene Corporation (NASDAQ:CELG) just came in strong this second quarter, thanks to great performances from pipeline drugs lymphoma treating Revlimid and Pomalyst, …
In a research report published Thursday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on shares of Celgene Corporation (NASDAQ:CELG), with a price …
Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,745 million for the second quarter of 2016, a 22 percent increase from the same period …
